Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Paukenschlag in den USA - diese Aktien könnten profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Actusnews Wire-Archiv vom 02.02.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
02.02.23GROUPE BOGART: FULL-YEAR 2022 TURNOVER AT EUR 293.0 MILLION (UP 19.2%) - UPDATE ON THE STATE OF RETAIL BUSINESS IN FRANCE AND ON THE OUTLOOK FOR 2022 EARNINGS568PRESS RELEASE Paris, 2 February 2023 BOGART (Euronext Paris - Compartment B - FR0012872141 - JBOG), which specialises in the creation, manufacture and sale of luxury fragrances and cosmetics...
► Artikel lesen
02.02.23ZCCM-IH Notice of Change in Company Secretary.345SENS ANNOUNCEMENT (the "Announcement") ISSUER ZCCM INVESTMENTS HOLDINGS PLC ("ZCCM-IH") Incorporated in the Republic of Zambia Company registration number: 119540000771 Share Code: ZCCM-IH ISIN:...
► Artikel lesen
02.02.23Artmarket.com: Assessing the liquidity of artworks with Artprice tools (Part 1 of 2)530The ease with which an artwork can be traded depends on several factors starting with the supply/demand balance for works by the artist who created it and the rarity of the individual piece in...
► Artikel lesen
02.02.23HYDROGEN REFUELING SOLUTIONS (HRS): GCK chooses HRS to speed up the implementation of of its charging solutions for hydrogen mobility638GCK CHOOSES HRS TO SPEED UP THE IMPLEMENTATION OF OF ITS CHARGING SOLUTIONS FOR HYDROGEN MOBILITY Grenoble, February 2, 2023 - HRS, the European designer and manufacturer of hydrogen refueling...
► Artikel lesen
02.02.23PHARNEXT: Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A584PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for...
► Artikel lesen